SequelSEC

DEXCOM INC DXCM

Surgical & Medical Instruments & Apparatus · CIK 0001093557 · Fiscal year ends 1231

Revenue
$4.66B
Fiscal year ended 2025-12-31
Operating income
$911.80M
Fiscal year ended 2025-12-31
Free cash flow
$1.08B
Fiscal year ended 2025-12-31

DEXCOM INC (DXCM) reported revenue of $4.66B and net income of $836.30M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from DEXCOM INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

DEXCOM INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$4.66B$4.03B$3.62B$2.91B$2.45B$1.93B$1.48B$1.03B$718.50M$573.30M
Cost of revenue$1.86B$1.59B$1.33B$1.03B$768.00M$646.60M$544.50M$367.70M$226.40M$194.90M
Gross profit$2.80B$2.44B$2.29B$1.88B$1.68B$1.28B$931.50M$663.90M$492.10M$378.40M
Operating income$911.80M$600.00M$597.70M$391.20M$265.80M$299.50M$142.30M-$186.30M-$42.50M-$63.90M
Net income$836.30M$576.20M$541.50M$341.20M$216.90M$549.70M$101.10M-$127.10M-$50.20M-$65.60M
Research & development$599.10M$552.40M$505.80M$484.20M$517.10M$359.90M$273.50M$199.70M$185.40M$156.10M
Weighted-average diluted sharesshares 405.50Mshares 412.70Mshares 425.50Mshares 427.50Mshares 428.80Mshares 420.40Mshares 92.30Mshares 88.20Mshares 86.30MUnavailable
Pretax income$1.09B$709.00M$710.40M$390.80M$256.80M$297.90M$104.20M-$126.50M-$48.60M-$64.90M
Income tax expense$252.10M$132.80M$168.90M$49.60M$39.90M-$251.80M$3.10M$600.00K$1.60M$700.00K
Diluted EPS$2.09$1.42$1.30$0.82$0.53$1.33$1.10$-1.44$-0.58Unavailable
Selling, general & administrative$1.29B$1.29B$1.19B$1.01B$810.50M$618.20M$515.70M$432.80M$349.20M$286.20M
General & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

DEXCOM INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$917.70M$606.10M$566.30M$642.30M$1.05B$817.60M$446.20M$1.14B$441.50M$94.50M
Total assets$6.34B$6.48B$6.26B$5.39B$4.93B$4.29B$2.40B$1.92B$904.10M$402.80M
Current assets$4.03B$4.30B$4.43B$3.67B$3.68B$3.42B$1.97B$1.70B$744.70M$280.00M
Total liabilities$3.59B$4.38B$4.20B$3.26B$2.89B$2.46B$1.51B$1.25B$484.70M$119.00M
Current liabilities$2.14B$2.93B$1.56B$1.84B$720.80M$614.10M$360.20M$222.40M$138.90M$102.40M
Total equity incl. NCI$2.75B$2.10B$2.07B$2.13B$2.04B$1.55B$882.60M$663.30M$419.40M$283.80M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$629.10M$542.60M$559.60M$306.70M$357.30M$234.70M$119.80M$70.70M$45.20M$45.40M
Accounts receivable$1.22B$1.01B$973.90M$713.30M$514.30M$428.50M$286.30M$226.70M$134.30M$101.70M
Goodwill$24.20M$22.80M$25.20M$25.70M$26.50M$19.30M$18.60M$18.70M$12.10M$11.30M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

DEXCOM INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow$1.44B$989.50M$748.50M$669.50M$442.50M$475.60M$314.50M$123.20M$92.00M$56.20M
Capital expenditures$363.50M$358.80M$236.60M$364.80M$389.20M$199.00M$180.00M$67.10M$66.00M$55.70M
Investing cash flow$536.00M-$207.50M-$507.20M-$521.50M-$216.10M-$1.02B-$1.02B-$139.80M-$144.40M-$55.90M
Financing cash flow-$1.69B-$734.80M-$318.60M-$552.50M$10.40M$912.10M$10.70M$710.40M$399.10M$8.10M
Net change in cash$311.80M$39.80M-$75.80M-$410.30M$235.40M$371.80M-$690.70M$695.60M$347.00M$8.40M
Stock-based compensation$159.60M$170.40M$150.80M$126.50M$113.40M$119.40M$102.70M$101.90M$106.20M$110.80M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$500.00M$750.00M$688.70M$557.70M$0$0$0$100.00M$0$0
Depreciation & amortization$251.80M$217.70M$186.00M$155.90M$102.00M$67.10M$48.70M$29.10M$16.10M$15.00M

Derived

DEXCOM INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow$1.08B$630.70M$511.90M$304.70M$53.30M$276.60M$134.50M$56.10M$26.00M$500.00K
Gross margin60.1%60.5%63.2%64.7%68.6%66.4%63.1%64.4%68.5%66.0%
Operating margin19.6%14.9%16.5%13.4%10.9%15.5%9.6%-18.1%-5.9%-11.1%
FCF margin23.1%15.6%14.1%10.5%2.2%14.4%9.1%5.4%3.6%0.1%
SBC / revenue3.4%4.2%4.2%4.3%4.6%6.2%7.0%9.9%14.8%19.3%
Current ratio1.88x1.47x2.84x1.99x5.11x5.58x5.47x7.64x5.36x2.73x
Revenue YoY growth15.6%11.3%24.5%18.8%27.1%30.5%43.1%43.6%25.3%Unavailable
Net margin17.9%14.3%14.9%11.7%8.9%28.5%6.8%-12.3%-7.0%-11.4%
R&D / revenue12.9%13.7%14.0%16.6%21.1%18.7%18.5%19.4%25.8%27.2%
CapEx / revenue7.8%8.9%6.5%12.5%15.9%10.3%12.2%6.5%9.2%9.7%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rate23.2%18.7%23.8%12.7%15.5%-84.5%3.0%UnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DXCM in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-05-01View SEC filing

Companies in the same industry

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 274600000 exceeds tolerance 4290500.000. Presentation or filing-vintage differences need review.